KIF2B

Across TCGA pan-cancer cohorts, KIF2B Mutation is linked to patient survival in 9 of 34 cancer types, making it a survival-associated KIF2B data layer compared with 13 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher KIF2B Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated KIF2B expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

UCEC, COAD, and KIRP are the cancer types where KIF2B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	All	0.974	0.614	.002	30	view →
COAD	OS	Median	All	0.612	0.884	<.001	19	view →
KIRP	OS	Median	All	0.272	0.885	.002	12	view →
LUAD	OS	Median	III,IV	0.167	0.690	<.001	6	view →
SKCM	OS	Median	IV	0.133	0.621	.019	6	view →
READ	OS	Median	All	0.278	0.710	.042	4	view →
GBM	DFS	Median	All	0.069	0.244	.022	3	view →
LIHC	OS	Median	III,IV	0.204	0.648	.030	3	view →
HNSC	DFS	Median	All	0.609	0.713	.044	2	view →

Pink = unfavorable, green = favorable. Showing the 9 strongest of 9 lineages.

KIF2B–UCEC (DFS)

Open the UCEC breakdown →